小胶质细胞在帕金森病病理进展中的作用

帕金森病是中老年人常见的中枢神经系统退行性疾病,研究表明小胶质细胞的活化及其介导的神经炎症在帕金森病的病程进展中发挥重要作用,适度干预小胶质细胞的活化有望延缓帕金森病的进程。小胶质细胞是中枢神经系统固有的巨噬细胞,Notch信号途径可以调控小鼠外周巨噬细胞的分化及功能。Notch通路也参与调控小胶质细胞的激活、细胞因子的表达、吞噬活性的变化等,而这与活化的小胶质细胞介导的帕金森病等神经退行性疾病的病情进展相关。因此,本文将综述Notch信号途径与小胶质细胞介导的相关疾病的研究进展。     

MicroRNA调控小胶质细胞极化在神经系统疾病中的作用和机制研究进展

小胶质细胞是定居于中枢神经系统的巨噬细胞,其激活介导的免疫炎症反应在多种神经系统疾病的病理进程中均扮演极其重要的角色。激活的小胶质细胞存在M1和M2两种形态、功能显著不同的极化类型。M1型细胞主要发挥杀菌和促炎作用,M2型细胞则具有抗炎和促进神经修复等功能。越来越多的证据表明,micro RNA(mi RNA)在不同极化状态的小胶质细胞中表达模式存在明显差异,mi RNA可以调控小胶质细胞的极化过程,并进一步影响神经疾病的病理进展。充分阐明疾病发病过程中小胶质细胞的极化亚型及其mi RNA调节机制,有助于深入认识小胶质细胞参与神经系统疾病发病的免疫病理机制,为寻找更加有效的神经疾病治疗新靶点提供理论依据。     

小胶质细胞介导的吞噬作用在神经退行性疾病中的研究进展

随着人口老龄化进程加剧,阿尔茨海默病和帕金森病等神经退行性疾病迄今为止已经成为一种全球性的健康危机之一。目前的研究进展表明,小胶质细胞与神经元的相互作用对中枢神经系统的稳态维持至关重要。神经退行性疾病研究,包括大规模全基因组关联分析或者脑影像学研究都提示,小胶质细胞在疾病早期大量激活。小胶质细胞是脑内一类吞噬细胞,新的细胞吞噬途径——细胞啃噬(trogocytosis)的发现为揭示小胶质细胞与存活神经元之间存在的密切关系提供了新的视角。本文将重点对神经退行性疾病发病过程中小胶质细胞介导的吞噬及啃噬作用以及分子机制的研究进展作一简要评述。     

小胶质细胞及相关神经退行性疾病

小胶质细胞(microglia,MG)是中枢神经系统(central nervous system,CNS)中重要的神经免疫细胞,它在中枢神经系统中广泛分布,对中枢神经系统起着重要的免疫监视作用。研究发现,神经退行性疾病如阿尔茨海默病(Alzheimer’s disease,AD)、帕金森病(Parkinson’s disease,PD)、肌萎缩性侧索硬化症(Amyotrophic lateral sclerosis,ALS)等与小胶质细胞有着密切的关系。因此,阐明小胶质细胞的致病机理对临床预防与治疗相关神经疾病有着重要的理论意义和实用价值。目前,对于小胶质细胞的功能及调节机制虽研究较多,但还不够系统,该文就近年来人们对小胶质细胞的致病机理及其相关神经退行性疾病的研究进展作一综述。     

小胶质细胞极化在中枢神经系统髓鞘再生中的作用研究进展

了解中枢神经系统髓鞘损伤再生的调控机制对多种中枢神经系统脱髓鞘疾病的治疗有重要意义。近年来研究发现,中枢神经系统中小胶质细胞的不同极化形式在调控髓鞘损伤再生中起到重要作用。在一系列细胞内外信号分子的介导下,M1型小胶质细胞会分泌一些促炎因子而加重髓鞘的损伤,而M2型小胶质细胞一方面可分泌抗炎分子和吞噬损伤坏死细胞而抑制炎症反应,为髓鞘再生创造条件;另一方面还能分泌多种神经营养因子,促进髓鞘修复。此外,最近研究发现M2型小胶质细胞在一定程度上还能促进少突胶质前体细胞的成熟分化,进而促进了中枢神经系统髓鞘的再生。这些研究结果提示,促进小胶质细胞的M2型极化可能成为治疗脱髓鞘疾病的新途径。     

自噬与小胶质细胞相关神经炎症

小胶质细胞是中枢神经系统中重要的神经免疫细胞,当中枢神经系统受到刺激后,小胶质细胞通过炎症反应来应对这种刺激,这种炎症反应在神经性疾病中具有重要作用。研究发现,小胶质细胞自噬在炎症的发生与发展中也发挥了重要作用,它能直接或间接地影响炎症反应,同时自身也被其他信号调控。自噬过程有利有弊,适当的自噬过程能促进疾病的恢复,自噬紊乱则使病情恶化,所以明确自噬的调控机制对治疗和预防相关疾病具有重要意义。本文综述了近年来自噬在小胶质细胞相关炎症中研究进展,以及其可能的调控机制,以期为相关研究人员提供一定帮助。     

小胶质细胞极化与抑郁症关系的研究进展

小胶质细胞控制着中枢神经系统主要的免疫功能,在各种精神疾病中发挥重要作用. 某些信号通路的激活引发的神经炎症与抑郁症的发生有着密切的关系. 小胶质细胞是神经炎症的主要介导者,不同的刺激促进小胶质细胞极化,不同极化类型的小胶质细胞能分泌多种炎性细胞因子,在神经炎症调节中具有重要的作用. 临床研究和体内外实验研究表明,抑郁症与小胶质细胞极化介导的神经炎症有关. 小胶质细胞极化参与抑郁症发生发展的可能机制包括NF-κB信号通路激活、呼吸爆发、补体受体3信号通路、NLRP3炎症激活、cannibalism受体1、Notch-1信号通路和过氧化物酶体增殖物激活受体γ的激活. 本文就小胶质细胞极化与抑郁关系的研究进展作一综述.     

小胶质细胞极化在抑郁症发病中的作用

应激可诱发抑郁症,严重影响人们的身心健康。小胶质细胞是中枢神经系统的主要免疫细胞,在各种神经退行性疾病中发挥重要作用。不同极化类型的小胶质细胞可分泌不同作用的炎症因子,介导神经炎症,与抑郁症的发生密切相关,但目前其机制尚不明确。抑郁症与应激、小胶质细胞极化和神经炎症等因素的相互作用有关。本文综述了小胶质细胞极化在抑郁症发病中的作用研究进展。     

Notch信号途径及其调控

Notch是一个进化上十分保守的跨膜受体蛋白家族,对无脊椎动物和脊椎动物发育过程中的细胞命运决定起重要作用。一条重要的Notch信号途径涉及Notch的“三步蛋白质水解”活化。许多相关分子和体内生化过程参与Notch信号途径调控。调控发生在不同水平,包括Notch-配体互作、受体和配体的运输、泛素化降解等。现就Notch受体、Notch信号途径及其所受的不同水平的调控进行综述。     

神经系统疾病中MicroRNA调控小胶质细胞极化机制研究

在多种神经系统的损伤和疾病中,神经炎症都发挥着重要的作用,而小胶质细胞是中枢炎症反映的重要招募者和执行者,是中枢主要的免疫监督细胞,是定居于中枢神经系统的巨噬细胞。本文通过分析小胶质细胞的极化,探讨了MiRNA参与小胶质细胞和巨噬细胞极化的调控,并且对在神经系统疾病中,MicroRNA影响小胶质细胞极化的重要性进行分析。     

A Spirulina-Enhanced Diet Provides Neuroprotection in an α-Synuclein Model of Parkinson's Disease

Inflammation in the brain plays a major role in neurodegenerative diseases. In particular, microglial cell activation is believed to be associated with the pathogenesis of neurodegenerative diseases, including Parkinson’s disease (PD). An increase in microglia activation has been shown in the substantia nigra pars compacta (SNpc) of PD models when there has been a decrease in tyrosine hydroxylase (TH) positive cells. This may be a sign of neurotoxicity due to prolonged activation of microglia in both early and late stages of disease progression. Natural products, such as spirulina, derived from blue green algae, are believed to help reverse this effect due to its anti-inflammatory/anti-oxidant properties. An adeno-associated virus vector (AAV9) for α-synuclein was injected in the substantia nigra of rats to model Parkinson''s disease and to study the effects of spirulina on the inflammatory response. One month prior to surgeries, rats were fed either a diet enhanced with spirulina or a control diet. Immunohistochemistry was analyzed with unbiased stereological methods to quantify lesion size and microglial activation. As hypothesized, spirulina was neuroprotective in this α-synuclein model of PD as more TH+ and NeuN+ cells were observed; spirulina concomitantly decreased the numbers of activated microglial cells as determined by MHCII expression. This decrease in microglia activation may have been due, in part, to the effect of spirulina to increase expression of the fractalkine receptor (CX3CR1) on microglia. With this study we hypothesize that α-synuclein neurotoxicity is mediated, at least in part, via an interaction with microglia. We observed a decrease in activated microglia in the rats that received a spirulina- enhanced diet concomitant to neuroprotection. The increase in CX3CR1 in the groups that received spirulina, suggests a potential mechanism of action.     

Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease

Alpha-synuclein protein is strongly implicated in the pathogenesis Parkinson''s disease. Increased expression of α-synuclein due to genetic multiplication or point mutations leads to early onset disease. While α-synuclein is known to modulate membrane vesicle dynamics, it is not clear if this activity is involved in the pathogenic process or if measurable physiological effects of α-synuclein over-expression or mutation exist in vivo. Macrophages and microglia isolated from BAC α-synuclein transgenic mice, which overexpress α-synuclein under regulation of its own promoter, express α-synuclein and exhibit impaired cytokine release and phagocytosis. These processes were affected in vivo as well, both in peritoneal macrophages and microglia in the CNS. Extending these findings to humans, we found similar results with monocytes and fibroblasts isolated from idiopathic or familial Parkinson''s disease patients compared to age-matched controls. In summary, this paper provides 1) a new animal model to measure α-synuclein dysfunction; 2) a cellular system to measure synchronized mobilization of α-synuclein and its functional interactions; 3) observations regarding a potential role for innate immune cell function in the development and progression of Parkinson''s disease and other human synucleinopathies; 4) putative peripheral biomarkers to study and track these processes in human subjects. While altered neuronal function is a primary issue in PD, the widespread consequence of abnormal α-synuclein expression in other cell types, including immune cells, could play an important role in the neurodegenerative progression of PD and other synucleinopathies. Moreover, increased α-synuclein and altered phagocytosis may provide a useful biomarker for human PD.     

Microglia: Activation in acute and chronic inflammatory states and in response to cardiovascular dysfunction

Microglia are the resident immune cells in the central nervous system and are constantly monitoring their environment. After an insult, they are activated and secrete both pro- and anti-inflammatory mediators. Thus, they can have both detrimental and protective actions. Microglia are activated in many conditions that involve chronic inflammation such as Alzheimer's and Parkinson's diseases and in neuropathic pain. Following cerebral ischemia and stroke, microglia are activated and acutely contribute to neuronal loss and infarct damage. Chronically, in this condition, neuroprotective actions of activated microglia include clearance of the dead cells and secretion of neurotrophins. Of great interest is the recent observation that following myocardial infarction, there is increased inflammation within the hypothalamus and a marked increase in activated microglia.     

Aquaporin 4: A key player in Parkinson's disease

Parkinson's disease (PD) is one of the most prevalent neurodegenerative diseases which occur in aged people worldwide. Given that a sequence of cellular and molecular mechanisms, including oxidative stresses, apoptosis, inflammatory pathways, microglia, astrocyte activation, and aquaporin 4 (AQP4) are associated with initiation and the progression of PD. AQP4 may affect various pathways (i.e., α-synuclein, inflammatory pathways, and microglia and astrocyte activation). Few reports have evaluated the relationship between AQP4 and PD-related cellular and molecular pathways. Here, for the first time, we highlighted the relationship between AQP4 and molecular mechanisms involved in PD pathogenesis.     

Partial depletion and repopulation of microglia have different effects in the acute MPTP mouse model of Parkinson’s disease

ObjectivesParkinson''s disease (PD) is a common neurodegenerative disorder characterized by the progressive and selective degeneration of dopaminergic neurons. Microglial activation and neuroinflammation are associated with the pathogenesis of PD. However, the relationship between microglial activation and PD pathology remains to be explored.Materials and MethodsAn acute regimen of MPTP was administered to adult C57BL/6J mice with normal, much reduced or repopulated microglial population. Damages of the dopaminergic system were comprehensively assessed. Inflammation‐related factors were assessed by quantitative PCR and Multiplex immunoassay. Behavioural tests were carried out to evaluate the motor deficits in MPTP‐challenged mice.ResultsThe receptor for colony‐stimulating factor 1 inhibitor PLX3397 could effectively deplete microglia in the nigrostriatal pathway of mice via feeding a PLX3397‐formulated diet for 21 days. Microglial depletion downregulated both pro‐inflammatory and anti‐inflammatory molecule expression at baseline and after MPTP administration. At 1d post‐MPTP injection, dopaminergic neurons showed a significant reduction in PLX3397‐fed mice, but not in control diet (CD)‐fed mice. However, partial microglial depletion in mice exerted little effect on MPTP‐induced dopaminergic injuries compared with CD mice at later time points. Interestingly, microglial repopulation brought about apparent resistance to MPTP intoxication.ConclusionsMicroglia can inhibit PD development at a very early stage; partial microglial depletion has little effect in terms of the whole process of the disease; and microglial replenishment elicits neuroprotection in PD mice.     

Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation

Apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase 3 family, is activated by oxidative stress. The death-signaling pathway mediated by ASK1 is inhibited by DJ-1, which is linked to recessively inherited Parkinson''s disease (PD). Considering that DJ-1 deficiency exacerbates the toxicity of the mitochondrial complex I inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), we sought to investigate the direct role and mechanism of ASK1 in MPTP-induced dopamine neuron toxicity. In the present study, we found that MPTP administration to wild-type mice activates ASK1 in the midbrain. In ASK1 null mice, MPTP-induced motor impairment was less profound, and striatal dopamine content and nigral dopamine neuron counts were relatively preserved compared to wild-type littermates. Further, microglia and astrocyte activation seen in wild-type mice challenged with MPTP was markedly attenuated in ASK1^−/− mice. These data suggest that ASK1 is a key player in MPTP-induced glial activation linking oxidative stress with neuroinflammation, two well recognized pathogenetic factors in PD. These findings demonstrate that ASK1 is an important effector of MPTP-induced toxicity and suggest that inhibiting this kinase is a plausible therapeutic strategy for protecting dopamine neurons in PD.     

Signaling mechanisms underlying inhibition of neuroinflammation by resveratrol in neurodegenerative diseases

Neurodegenerative diseases (NDs), including Alzheimer's disease (AD), and Parkinson's disease (PD), are characterized by the progressive loss of the structure and function of neurons and most commonly occur in the elderly population. Microglia are resident macrophages of the central nervous system (CNS). The neuroinflammation caused by excessive microglial activation is closely related to the onset and progression of many NDs. Therefore, inhibiting excessive microglial activation is a potential drug target for controlling neuroinflammation. In recent years, natural products as modulators of microglial polarization have attracted considerable attention in the field of NDs therapy. Furthermore, resveratrol (RES) has been found to have a protective effect in NDs through the inhibition of microglial activation and the regulation of neuroinflammation. In this review, we mainly summarize the therapeutic potential of RES and its various molecular mechanisms in the treatment of NDs through the modulation of microglial activation.     

PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2

Neuroinflammation is a major risk factor in Parkinson's disease (PD). Alternative approaches are needed to treat inflammation, as anti-inflammatory drugs such as NSAIDs that inhibit cyclooxygenase-2 (COX-2) can produce devastating side effects, including heart attack and stroke. New therapeutic strategies that target factors downstream of COX-2, such as prostaglandin J2 (PGJ2), hold tremendous promise because they will not alter the homeostatic balance offered by COX-2 derived prostanoids. In the current studies, we report that repeated microinfusion of PGJ2 into the substantia nigra of non-transgenic mice, induces three stages of pathology that mimic the slow-onset cellular and behavioral pathology of PD: mild (one injection) when only motor deficits are detectable, intermediate (two injections) when neuronal and motor deficits as well as microglia activation are detectable, and severe (four injections) when dopaminergic neuronal loss is massive accompanied by microglia activation and motor deficits. Microglia activation was evaluated in vivo by positron emission tomography (PET) with [¹¹C](R)PK11195 to provide a regional estimation of brain inflammation. PACAP27 reduced dopaminergic neuronal loss and motor deficits induced by PGJ2, without preventing microglia activation. The latter could be problematic in that persistent microglia activation can exert long-term deleterious effects on neurons and behavior. In conclusion, this PGJ2-induced mouse model that mimics in part chronic inflammation, exhibits slow-onset PD-like pathology and is optimal for testing diagnostic tools such as PET, as well as therapies designed to target the integrated signaling across neurons and microglia, to fully benefit patients with PD.     

Microglia Acquire Distinct Activation Profiles Depending on the Degree of α-Synuclein Neuropathology in a rAAV Based Model of Parkinson's Disease

Post-mortem analysis of brains from Parkinson''s disease (PD) patients strongly supports microglia activation and adaptive immunity as factors contributing to disease progression. Such responses may be triggered by α-synuclein (α-syn), which is known to be the main constituent of the aggregated proteins found in Lewy bodies in the brains of PD patients. To investigate this we used a recombinant viral vector to express human α-syn in rat midbrain at levels that induced neuronal pathology either in the absence or the presence of dopaminergic cell death, thereby mimicking early or late stages of the disease. Microglia activation was assessed by stereological quantification of Mac1+ cells, as well as the expression patterns of CD68 and MCH II. In our study, when α-syn induced neuronal pathology but not cell death, a fast transient increase in microglia cell numbers resulted in the long-term induction of MHC II+ microglia, denoting antigen-presenting ability. On the other hand, when α-syn induced both neuronal pathology and cell death, there was a delayed increase in microglia cell numbers, which correlated with long-lasting CD68 expression and a morphology reminiscent of peripheral macrophages. In addition T-lymphocyte infiltration, as judged by the presence of CD4+ and CD8+ cells, showed distinct kinetics depending on the degree of neurodegeneration, and was significantly higher when cell death occurred. We have thus for the first time shown that the microglial response differs depending on whether α-syn expression results on cell death or not, suggesting that microglia may play different roles during disease progression. Furthermore, our data suggest that the microglial response is modulated by early events related to α-syn expression in substantia nigra and persists at the long term.